hammerhead ribozyme

01/01/2000 - "We evaluated the efficacy of an anti-K-ras hammerhead ribozyme targeted against GUU-mutated codon 12 of the K-ras gene in cultured pancreatic carcinoma cell lines. "
12/18/1998 - "We have evaluated the efficacy of an anti-K-ras hammerhead ribozyme targeted against GUU-mutated codon 12 of the K-ras gene in a cell-free system as well as in cultured pancreatic carcinoma cell lines. "
12/18/1998 - "Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells."
06/01/2004 - "In this study, we designed a hammerhead ribozyme directed against K-ras mRNA at codon 25 [K-ras Rz (25)], and investigated its efficacy in a cultured human pancreatic carcinoma cell line, MIA PaCa-2. "
07/01/1999 - "In the present study we investigated whether a hammerhead ribozyme is capable of cleaving mutated Ki-ras mRNA in a pancreatic carcinoma cell line and whether antisense effects contribute to the activity of the ribozyme. "

10/01/2007 - "We reduced the expression of this molecule in both PC-3 and DU-145 cell lines using hammerhead ribozyme technology, and we examined various important characteristics associated with cancer progression and development in vitro. "
05/01/2005 - "Expression cassettes of human SDF-1 and hammerhead ribozyme transgenes specifically targeting human SDF-1 were constructed and used to over-express SDF-1 or to knockout the expression of SDF-1 in cancer cells, respectively. "
09/25/1998 - "To mimic the downmodulation of p16INK4a commonly seen in cancer, we designed and characterized a hammerhead ribozyme against exon E1alpha of the murine pl6INK4a transcript. "
08/19/1994 - "To assess the role of PTN in tumor growth, we inactivated the PTN gene with PTN-targeted hammerhead ribozyme constructs. "
06/01/2002 - "Thus, hammerhead ribozyme against gamma-GCS is suggested to have potential as a cancer gene therapy to reduce the resistance of malignant cells to ionizing radiation and anti-cancer drugs."

03/01/2010 - "In this study, we attempt to reverse the malignant phenotype of the breast cancer cell line, MCF-7, using a HER-2-specific hammerhead ribozyme. "
08/01/2001 - "This study examined a transgene-consisting of a combination of U1snRNA, hammerhead ribozyme, and antisense, designed to inhibit c-met expression-and its impact on the migration and in vitro invasion of breast cancer cells. "
03/01/2016 - "Knock-down of SEMA3C was performed in MDA-MB-231 and MCF-7 breast cancer cell lines using anti-SEMA3C hammerhead ribozyme transgenes. "
04/01/2013 - "We knocked-down the expression of AAMP through transfection of MCF-7 and MDA-MB-231 breast cancer cells with a hammerhead ribozyme transgene (MCF-7(AAMPrib) and MDA-MB-231(AAMPrib)) and examined the impact on cell function using in vitro assays. "
11/01/2010 - "We first constructed a hammerhead ribozyme transgene to knock down Ehm2 expression in breast cancer cells. "

02/01/2006 - "The aim of this study was to evaluate the efficacy of hammerhead ribozyme to the proliferating cell nuclear antigen (PCNA-Rz) and 5-fluorouracil (5-FU) in experimental choroidal neovascularization (CNV) model in rats. "

08/01/1999 - "In this study, the therapeutic efficacy of a hammerhead ribozyme targeting the mutated H-ras oncogene was investigated in an experimental bladder cancer model using a recombinant adenovirus as delivery vehicle. "